Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Identifieur interne : 000722 ( Ncbi/Merge ); précédent : 000721; suivant : 000723Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Auteurs : Yun J. Kim [Canada] ; Masanori Ichise ; James R. Ballinger ; Douglas Vines ; Sean S. Erami ; Tatsuro Tatschida ; Anthony E. LangSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Aged, Brain (physiopathology), Brain (radionuclide imaging), Diagnosis, Differential, Dopamine Plasma Membrane Transport Proteins, Female, Humans, Iodine Radioisotopes (diagnostic use), Male, Membrane Glycoproteins, Membrane Transport Proteins (physiology), Middle Aged, Multiple System Atrophy (physiopathology), Multiple System Atrophy (radionuclide imaging), Nerve Tissue Proteins, Neurologic Examination, Parkinson Disease (physiopathology), Parkinson Disease (radionuclide imaging), Receptors, Dopamine D2 (physiology), Sensitivity and Specificity, Supranuclear Palsy, Progressive (physiopathology), Supranuclear Palsy, Progressive (radionuclide imaging), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , diagnostic use : Iodine Radioisotopes.
- chemical , physiology : Membrane Transport Proteins, Receptors, Dopamine D2.
- chemical : Dopamine Plasma Membrane Transport Proteins, Membrane Glycoproteins, Nerve Tissue Proteins.
- physiopathology : Brain, Multiple System Atrophy, Parkinson Disease, Supranuclear Palsy, Progressive.
- radionuclide imaging : Brain, Multiple System Atrophy, Parkinson Disease, Supranuclear Palsy, Progressive.
- Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Neurologic Examination, Sensitivity and Specificity, Tomography, Emission-Computed, Single-Photon.
Abstract
It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The objective of this work was to investigate whether combined pre- and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]beta-CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa-naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa-untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP.
PubMed: 11921116
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B29
- to stream PubMed, to step Curation: 003B29
- to stream PubMed, to step Checkpoint: 003B54
Links to Exploration step
pubmed:11921116Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.</title><author><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J" last="Kim">Yun J. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name></author><author><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R" last="Ballinger">James R. Ballinger</name></author><author><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name></author><author><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S" last="Erami">Sean S. Erami</name></author><author><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11921116</idno><idno type="pmid">11921116</idno><idno type="wicri:Area/PubMed/Corpus">003B29</idno><idno type="wicri:Area/PubMed/Curation">003B29</idno><idno type="wicri:Area/PubMed/Checkpoint">003B54</idno><idno type="wicri:Area/Ncbi/Merge">000722</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.</title><author><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J" last="Kim">Yun J. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name></author><author><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R" last="Ballinger">James R. Ballinger</name></author><author><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name></author><author><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S" last="Erami">Sean S. Erami</name></author><author><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Brain (physiopathology)</term><term>Brain (radionuclide imaging)</term><term>Diagnosis, Differential</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (physiology)</term><term>Middle Aged</term><term>Multiple System Atrophy (physiopathology)</term><term>Multiple System Atrophy (radionuclide imaging)</term><term>Nerve Tissue Proteins</term><term>Neurologic Examination</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Sensitivity and Specificity</term><term>Supranuclear Palsy, Progressive (physiopathology)</term><term>Supranuclear Palsy, Progressive (radionuclide imaging)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Membrane Transport Proteins</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Multiple System Atrophy</term><term>Parkinson Disease</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Multiple System Atrophy</term><term>Parkinson Disease</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Sensitivity and Specificity</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The objective of this work was to investigate whether combined pre- and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]beta-CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa-naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa-untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11921116</PMID><DateCreated><Year>2002</Year><Month>03</Month><Day>28</Day></DateCreated><DateCompleted><Year>2002</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.</ArticleTitle><Pagination><MedlinePgn>303-12</MedlinePgn></Pagination><Abstract><AbstractText>It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The objective of this work was to investigate whether combined pre- and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]beta-CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa-naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa-untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yun J</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichise</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ballinger</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Vines</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Erami</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Tatschida</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493214">SLC6A3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050483">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007457">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008562">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019578">Multiple System Atrophy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11921116</ArticleId><ArticleId IdType="pii">10.1002/mds.10042</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R" last="Ballinger">James R. Ballinger</name><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S" last="Erami">Sean S. Erami</name><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name></noCountry><country name="Canada"><noRegion><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J" last="Kim">Yun J. Kim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000722 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000722 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11921116
|texte= Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11921116" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |